Chengru Yang^1,#, Zhiyu Wang^1,#, Shaowu Bi¹, Xinmiao Zhang¹, Zhaoqiang Xu¹, Yifei Ge¹, Tianjie Zhang¹, Nan Wang¹, Yi Xu^{1,2,3,4,5,6,7,8,9,*}, Xiangyu Zhong^1,*

Oncology Research, Vol.33, No.11, pp. 3207-3229, 2025, DOI:10.32604/or.2025.066150 - 22 October 2025

Abstract Pancreatic cancer (PC) is an extremely aggressive cancer of the digestive system with insidious onset and the lack of effective biomarkers, resulting in late-stage diagnosis and poor prognosis. Exosomal non-coding RNAs (ncRNAs) are key mediators of intercellular communication that drive PC initiation and advancement. By modulating gene expression, they impact tumor microenvironment (TME) remodeling, proliferation, migration, apoptosis, and immune evasion. Critically, exosomal ncRNAs serve as promising biomarkers for early diagnosis and prognostic assessment. This review summarizes the current research achievements regarding exosomal ncRNAs in PC, systematically elaborating on their roles in tumor occurrence, metastasis, chemoresistance More >

Oncology Research Editorial Offfce

Oncology Research, Vol.33, No.9, pp. 2597-2597, 2025, DOI:10.32604/or.2025.071883 - 28 August 2025

Abstract This article has no abstract. More >

David A de la Garza-Kalife¹, Verónica L Loaiza-Gutiérrez¹, Esther Alhelí Hernández-Tobías², Carlos A González-Villarreal³, Jose Francisco Islas¹, Michelle G Santoyo-Suárez¹, Elsa N Garza-Treviño^1,*, Paulina Delgado-Gonzalez^1,*

Oncology Research, Vol.33, No.9, pp. 2243-2262, 2025, DOI:10.32604/or.2025.065222 - 28 August 2025

Abstract Emerging evidence highlights the potential of bioactive compounds, particularly polyphenols, as adjunctive therapeutic agents in the treatment of pancreatic cancer (PC), one of the most aggressive malignancies. This review focuses on epigallocatechin gallate (EGCG) and resveratrol due to their extensively documented anticancer activity, favorable safety profiles, and their unique ability to modulate multiple signaling pathways relevant to pancreatic tumorigenesis. Among polyphenols, these two have shown superior anti-cancer activity, epigenetic regulatory effects, and synergy with standard chemotherapies in preclinical pancreatic cancer models. Resveratrol exhibits anti-proliferative effects by modulating key signaling pathways, including phosphatidylinositol 3 kinase (PI3K)/protein… More > Graphic Abstract

Xinxin Hu^1,2,#, Yuye Xue^3,#, Fei Fang⁴, Jie Li², Xiaofeng Yuan², Guang Cheng⁵, Hailong Yuan³, Yongqiang Zhang², Yuefei Zhou⁵, Shuangwu Yang⁵, Pengcheng Qiu^2,*, Yunyang Lu², Haifeng Tang^2,*

Oncology Research, Vol.33, No.9, pp. 2491-2506, 2025, DOI:10.32604/or.2025.064454 - 28 August 2025

Abstract Objectives: The Sorbin and SH3 domain containing 1 (SORBS1), a protein linked to insulin signaling CBL interaction, was investigated for its role in pancreatic cancer apoptosis. This study explored polyphyllin H (PPH)’s ability to restore SORBS1-knockdown-mediated repair functions. Methods: PANC-1 cells were divided into Blank, overexpression (OE), and knockdown groups. CCK-8 assays assessed proliferation and drug toxicity. Western blot and flow cytometry analyzed SORBS1 levels and PPH effects. Comet assays quantified DNA damage. Subcutaneous xenograft tumors in nude mice (Blank vs. knockdown) were treated with PPH to evaluate in vivo efficacy. SORBS1-H2AX gene correlation was analyzed… More > Graphic Abstract

QIAN LI^1,#, SHUNPENG ZHU^1,#, MINGXIAN ZHU², FANG WANG^1,*, JINHUA ZHOU^1,*

Oncology Research, Vol.33, No.7, pp. 1757-1767, 2025, DOI:10.32604/or.2025.062539 - 26 June 2025

Abstract Objectives: Our previous research demonstrated that SIC-19, an innovative inhibitor of salt-inducible kinase 2 (SIK2), effectively reduces SIK2 protein levels through the ubiquitin-proteasome pathway and exhibits synthetic lethal effects with poly ADP-ribose polymerase (PARP) inhibitors in ovarian cancer. However, the role of SIC-19 in triple-negative breast cancer (TNBC) and pancreatic cancer (PC) remains poorly defined. This study aims to investigate whether SIC-19 combined with PARP inhibitors can induce synthetic lethal effects in TNBC and PC. Methods: Cell lines with high SIK2 expression were identified through Western blot analysis. The combination’s impact was evaluated using Cell… More >

FANGFANG HU¹, ZHIBIN BAI², YANG WANG¹, HAODONG TANG³, JIAHUA ZHOU^1,*

Oncology Research, Vol.33, No.7, pp. 1723-1737, 2025, DOI:10.32604/or.2025.059631 - 26 June 2025

Abstract Background: Kinesin-14 family protein 1 (KIFC1) is abnormally overexpressed in various cancers, and the transcription factor ETS variant 1 (ETV1) is an oncogenic transcription factor in tumors. The potential binding sites on the KIFC1 promoter by ETV1 were observed; however, no evidence supports that ETV1 targets KIFC1. Aims: This study aimed to investigate the relationship between KIFC1 and ETV1, and their effects and mechanisms in pancreatic cancer. Methods: Pan-cancer analysis of KIFC1 expression was performed in GEPIA2 database. KIFC1 expression levels were determined by immunohistochemistry (IHC) in our pancreatic cancer cohort. The correlation between KIFC1… More >

Jae Hyeong Kim¹, Yuna Youn¹, Jin-Hyeok Hwang^1,2,*

BIOCELL, Vol.49, No.4, pp. 681-700, 2025, DOI:10.32604/biocell.2025.062144 - 30 April 2025

Abstract Objectives: SLFN11 (Schlafen-11) enhances sensitivity to DNA-damaging agents (DDAs) and DNA damage response (DDR) inhibitors in various cancer types. However, its function in pancreatic cancer (PC) remains largely unknown. This research aims to investigate the expression patterns of SLFN11 and other SLFN family members in PC and their correlation with drug sensitivity. Methods: SLFN11 expression and genetic alterations were analyzed using publicly available datasets (TCGA and GTEx). Functional studies, including cell cycle, apoptosis assays, and proliferation assays, were performed in SLFN11-knockdown and SLFN11-knockout (KO) PC cells. The relationship between SLFN11 expression and drug responsiveness was assessed via the CellMiner… More >

Oncology Research Editorial Office

Oncology Research, Vol.33, No.3, pp. 735-735, 2025, DOI:10.32604/or.2024.056907 - 28 February 2025

Abstract This article has no abstract. More >

ZHEN WANG¹, JUN FU¹, SAISAI ZHU¹, HAODONG TANG², KUI SHI¹, JIHUA YANG³, MENG WANG³, MENGGE WU¹, DUNFENG QI^1,*

Oncology Research, Vol.32, No.12, pp. 1851-1866, 2024, DOI:10.32604/or.2024.055286 - 13 November 2024

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) has a rich and complex tumor immune microenvironment (TIME). M2 macrophages are among the most extensively infiltrated immune cells in the TIME and are necessary for the growth and migration of cancers. However, the mechanisms and targets mediating M2 macrophage infiltration in pancreatic cancer remain elusive. Methods: The M2 macrophage infiltration score of patients was assessed using the xCell algorithm. Using weighted gene co-expression network analysis (WGCNA), module genes associated with M2 macrophages were identified, and a predictive model was designed. The variations in immunological cell patterns, cancer mutations, and… More > Graphic Abstract

Luda Chen¹, Kuangzhu Bao², Ying Chen², Jingang Hao^2,*, Jianfeng He^1,3,*

CMC-Computers, Materials & Continua, Vol.79, No.1, pp. 409-427, 2024, DOI:10.32604/cmc.2024.048507 - 25 April 2024

Abstract Pancreatic diseases, including mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC), present with similar imaging features, leading to diagnostic complexities. Deep Learning (DL) methods have been shown to perform well on diagnostic tasks. Existing DL pancreatic lesion diagnosis studies based on Magnetic Resonance Imaging (MRI) utilize the prior information to guide models to focus on the lesion region. However, over-reliance on prior information may ignore the background information that is helpful for diagnosis. This study verifies the diagnostic significance of the background information using a clinical dataset. Consequently, the Prior Difference Guidance Network (PDGNet)… More >